Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

New treatments for sexual dysfunction and cardiovascular disorders disclosed by BMS

Nov. 3, 2000

EMD-221829, a new PDE5 inhibitor: correlation of pharmacokinetics and pharmacodynamics

Nov. 2, 2000

Nastech's intranasal apomorphine enters phase II for MED

Oct. 31, 2000

Antifibrotic agents patented by Sumitomo

Oct. 27, 2000

ASA 2000: Ono-5046 protects against I/R-induced renal injury via effect on leukocyte activation

Oct. 25, 2000

KMD-3213: binding kinetics and pharmacological activity correlated in vivo

Oct. 25, 2000

Vivus withdraws Alibra NDA

Oct. 23, 2000

New series of PDE5 inhibitors and their use described by Sanofi-Synthelabo

Oct. 19, 2000

Abbott researchers design novel water-soluble K+ channel openers

Oct. 17, 2000

Novel 5-HT reuptake inhibitors specifically claimed for use in premature ejaculation

Oct. 16, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...